Birgit Girshick
Net Worth
Last updated:
What is Birgit Girshick net worth?
The estimated net worth of Ms. Birgit Girshick is at least $18,099,798 as of 10 Jan 2024. She owns shares worth $7,049,611 as insider, has earned $5,572,667 from insider trading and has received compensation worth at least $5,477,520 in Charles River Laboratories International, Inc..
What is the salary of Birgit Girshick?
Ms. Birgit Girshick salary is $912,920 per year as Corporation Executive Vice President & Chief Operating Officer in Charles River Laboratories International, Inc..
How old is Birgit Girshick?
Ms. Birgit Girshick is 55 years old, born in 1970.
What stocks does Birgit Girshick currently own?
As insider, Ms. Birgit Girshick owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Charles River Laboratories International, Inc. (CRL) | Corporation Executive Vice President & Chief Operating Officer | 44,449 | $158.6 | $7,049,611 |
What does Charles River Laboratories International, Inc. do?
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Birgit Girshick insider trading
Charles River Laboratories International, Inc.
Ms. Birgit Girshick has made 22 insider trades between 2019-2024, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 18,311 units of CRL stock on 6 Apr 2021. As of 10 Jan 2024 she still owns at least 44,449 units of CRL stock.
Charles River Laboratories International key executives
Charles River Laboratories International, Inc. executives and other stock owners filed with the SEC:
- Mr. David Ross Smith (59) Corporation Executive Vice President & Chief Financial Officer
- Mr. James C. Foster (74) Chairman, Chief Executive Officer & Pres
- Mr. Joseph W. LaPlume (51) Corporation Executive Vice President of Corporation Devel. & Strategy
- Mr. William D. Barbo (64) Chief Commercial Officer & Corporation Executive Vice President
- Ms. Birgit Girshick (55) Corporation Executive Vice President & Chief Operating Officer